# US Biomarker Market

> United States Biomarker Market Research Report: Size, Share, Trend Analysis By Types (Predictive Biomarkers, Diagnostic Biomarkers, Prognostic Biomarkers, Pharmacodynamic Biomarkers, Research Biomarkers) By End-user (Pharmaceutical Companies, Clinical Laboratories, Research Institutions, Diagnostic Laboratories) By Technology (Omics Technologies, Imaging Technologies, Bioinformatics, Mass Spectrometry, PCR Technologies) By Applications (Oncology, Cardiovascular, Neurology, Infectious Diseases, Autoimmune Diseases) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 9.92%
- **2024:** $ 16.98 Billion
- **2025:** $ 18.66 Billion
- **2035:** $ 48.08 Billion
- **Key Players:** Roche (CH), Thermo Fisher Scientific (US), Abbott Laboratories (US), Agilent Technologies (US), Bio-Rad Laboratories (US), Merck KGaA (DE), Illumina (US), Qiagen (DE), PerkinElmer (US)

**Report ID:** MRFR/LS/17158-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-biomarker-market-18686

---

## Market Summary

## US Biomarker Market Highlighted Trends & Dynamics

The US biomarkers market is experiencing a rising demand driven primarily by innovations in personalized medicine. Biomarkers contribute considerably to personalized medicine by creating more differentiated methods of diagnosis, prognosis and therapy selection based on a patient’s individual biological markers.

The latest trend in the field of medicine is early detection and monitoring due to an increasing number of chronic diseases like cancer, diabetes, cardiovascular disorders. Biomarkers provide measurable indicators that signal the existence or progression of diseases, facilitating early detection and intervention leading to better patient outcomes.

Demand for biomarkers arises from their functions in both diagnostics and prognostics. Biomarker-based tests help in early detection of diseases, leading to timely start of treatment. Moreover, the biomarkers are used to predict disease progression hence enabling health care providers to establish appropriate treatment regimes based on an individual’s risk profile.

The increase in precision medicine initiatives at both the research and clinical level leads to growth of biomarkers market. With individualized treatment approaches becoming more common in healthcare institutions, biomarkers help to identify patient-specific characteristics that affect response selection.

Biomarkers have a crucial role in drug discovery and clinical trials used by the pharmaceutical industry, biotechnology sectors has led to demand for these. It is essential for the streamlining of drug development to have biomarkers, which act as indicators in terms of efficacy and safety or response.

The combination of modern omics technologies, such as genomic proteomics metabolomics has led to a revolution in biomarker discovery and validation. These technologies facilitate detection of a larger portion biomarkers with greater selectivity and sensitivity which makes applications more precise in diagnosis therapy.

One of the critical factors driving demand for biomarkers is early disease detection. More and more governments, healthcare organizations, as well as research institutions realize the value of early intervention aimed at improving outcomes in patients while addressing affordability issues associated with growing numbers of ill persons. The cancer biomarkers segment is showing a high growth rate, due to the requirements for non-invasive and reliable tools for diagnosis of cancers as well as monitoring its progress. Biomarkers like circulating tumor cells, cell-free DNA and some specific protein markers are drastically changing the way cancer is detected or managed.

Due to the population getting old in US, there is an increase need for biomarkers specifically with respect to age associated diseases. Biomarkers provide valuable information about age-related diseases, which allow taking preventive healthcare measures and developing individualized treatment regimens for the older people.

The integration of biomarker panels or multiplex biomarker assays is a developing trend. This method enables physicians to consider multiple biological parameters at the same time, thereby providing a better understanding of how healthy someone really is and enabling more appropriate diagnoses and treatments.

## Market Drivers

### Rising Incidence of Chronic Diseases

The increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders is a major driver for the biomarker market. According to the Centers for Disease Control and Prevention (CDC), chronic diseases account for 7 out of 10 deaths in the US, highlighting the urgent need for effective diagnostic tools. Biomarkers play a crucial role in early detection, prognosis, and treatment monitoring of these diseases. The demand for personalized medicine is also on the rise, as patients seek tailored treatment options based on their unique biomarker profiles. This trend is expected to boost the biomarker market significantly, with estimates suggesting a market value exceeding $50 billion by 2030. Consequently, healthcare providers are increasingly adopting biomarker-based diagnostics to improve patient outcomes.

### Growing Investment in Precision Medicine

The biomarker market is benefiting from the growing investment in precision medicine initiatives. As healthcare shifts towards more personalized approaches, biomarkers are becoming essential for tailoring treatments to individual patients. The National Institutes of Health (NIH) has allocated substantial funding towards precision medicine research, which is expected to enhance the development of biomarker-based diagnostics and therapeutics. This investment is likely to foster collaborations between academic institutions and industry players, further driving innovation in the biomarker market. Additionally, the increasing number of clinical trials focusing on biomarker-driven therapies is indicative of the market's potential. With the precision medicine market projected to reach $100 billion by 2026, the biomarker market is poised for substantial growth.

### Regulatory Support for Biomarker Development

Regulatory bodies in the US are increasingly recognizing the importance of biomarkers in drug development and diagnostics, which is positively impacting the biomarker market. The Food and Drug Administration (FDA) has established guidelines for the validation and approval of biomarker-based tests, streamlining the process for developers. This regulatory support is encouraging pharmaceutical companies to invest in biomarker research and development, as it reduces the time and cost associated with bringing new diagnostics to market. Furthermore, the FDA's initiatives to promote the use of biomarkers in clinical trials are likely to enhance the efficiency of drug development processes. As a result, the biomarker market is expected to expand, with a projected growth rate of around 10% annually over the next five years.

### Increased Awareness and Education on Biomarkers

There is a growing awareness and education surrounding the role of biomarkers in healthcare, which is driving the biomarker market. Healthcare professionals and patients alike are becoming more informed about the benefits of biomarker testing for disease prevention, diagnosis, and treatment. Educational initiatives by medical organizations and advocacy groups are contributing to this trend, emphasizing the importance of biomarkers in personalized medicine. As awareness increases, so does the demand for biomarker-based tests, leading to a more competitive market landscape. The biomarker market is likely to see a rise in new entrants and innovations as stakeholders seek to meet the evolving needs of healthcare providers and patients. This heightened awareness is expected to contribute to a market growth rate of approximately 8% over the next few years.

### Technological Advancements in Biomarker Discovery

The biomarker market is experiencing a surge due to rapid technological advancements in biomarker discovery. Innovations in genomics, proteomics, and metabolomics are enabling researchers to identify and validate biomarkers with unprecedented accuracy. For instance, next-generation sequencing (NGS) technologies have reduced the cost of genomic analysis significantly, making it more accessible for research and clinical applications. The market is projected to grow at a CAGR of approximately 12% from 2025 to 2030, driven by these advancements. Furthermore, the integration of artificial intelligence in data analysis is enhancing the efficiency of biomarker identification, thereby propelling the biomarker market forward. As a result, stakeholders are increasingly investing in these technologies to stay competitive in the evolving landscape.

## Future Outlook

The [Biomarker Market](https://www.marketresearchfuture.com/reports/biomarker-market-1941) is projected to grow at a 9.92% CAGR from 2025 to 2035, driven by advancements in personalized medicine, increased R&D investments, and rising demand for early disease detection.

**New opportunities:**

- Development of point-of-care biomarker testing devices Expansion of biomarker-based companion diagnostics Investment in AI-driven biomarker discovery platforms

By 2035, the biomarker market is expected to achieve substantial growth, driven by innovation and strategic investments.

## Segment Insights

### By Type: Diagnostic Biomarkers (Largest) vs. Predictive Biomarkers (Fastest-Growing)

The US biomarker market has seen a diverse distribution among its key segments. Diagnostic biomarkers currently hold the largest share, reflecting their critical role in disease detection and management. Meanwhile, predictive biomarkers, characterized by their ability to foresee treatment responses, are emerging rapidly in the market, capturing growing attention from both researchers and clinicians alike. Growth trends indicate a robust expansion in the predictive biomarkers segment, fueled by advances in genomics and personalized medicine. The increasing emphasis on tailored therapies is driving research and development efforts, making predictive biomarkers the fastest-growing segment. Additionally, the rising demand for early diagnosis and targeted treatments is further propelling market growth across all segments.

Diagnostic Biomarkers (Dominant) vs. Research Biomarkers (Emerging)

Diagnostic [biomarkers](https://www.marketresearchfuture.com/reports/renal-biomarker-market-43495) play a dominant role in the US biomarker market, primarily serving to identify diseases in their early stages, ensuring timely interventions. Their established presence in clinical practices has solidified their market superiority. Conversely, research biomarkers are an emerging segment, often utilized in laboratory settings for understanding disease mechanisms and treatment pathways. Despite being less mature, they are gaining traction due to increasing investments in research and development, with a focus on understanding complex diseases. Their evolving nature and application in clinical trials represent a critical area of growth within the market, highlighting the varied dynamics among the different biomarker types.

### By Application: Oncology (Largest) vs. Autoimmune Diseases (Fastest-Growing)

The US biomarker market exhibits a diverse application landscape, with oncology commanding the largest share, driven by the increasing prevalence of cancer and advancements in personalized medicine. Other significant segments such as cardiovascular and neurology also contribute notably, but they lag behind oncology in market presence. Emerging applications like autoimmune diseases are witnessing rapid growth, attributed to heightened awareness, improved diagnostic techniques, and a rise in autoimmune disorders. This is complemented by technological innovations and the development of targeted therapies, indicating a promising future for this segment in the US biomarker market.

Oncology (Dominant) vs. Autoimmune Diseases (Emerging)

Oncology represents the dominant application in the US biomarker market as it encompasses a wide array of diagnostic and therapeutic solutions tailored to cancer care. This segment benefits from robust research funding and increased investments in oncology therapeutics. In contrast, autoimmune diseases are emerging rapidly, characterized by a growing recognition of these conditions and their complex diagnostics. The market for autoimmune biomarkers is expanding due to advances in molecular technology, which are enhancing detection capabilities. Both segments play crucial roles in improving patient outcomes, yet oncology remains the established leader while autoimmune diseases are on a trajectory of significant growth.

### By Technology: Omics Technologies (Largest) vs. PCR Technologies (Fastest-Growing)

The technology segment of the US biomarker market showcases a diverse distribution of market share across different technologies. Omics Technologies hold a significant portion of the market, driven by advancements in genomics and proteomics, making them a substantial player in biomarker discovery and development. Imaging Technologies and Mass Spectrometry also contribute notably, representing essential methods for visualizing and analyzing biomarkers. Meanwhile, PCR Technologies, although smaller in size, are rapidly gaining traction due to their increasing application in diagnostics and research. Growth trends within this segment are influenced by technological advancements and rising demand for precision medicine. The push for personalized health care has accelerated the adoption of emerging technologies, particularly Bioinformatics and PCR Technologies, as they enable detailed analysis and rapid results. The integration of AI and machine learning with traditional biomarker technologies is enhancing efficiency and driving growth, positioning the US biomarker market towards a more technology-driven future.

Technology: Omics Technologies (Dominant) vs. PCR Technologies (Emerging)

Omics Technologies dominate the technology segment due to their comprehensive approach to understanding biological systems at a molecular level. This segment leverages various methodologies including genomics, transcriptomics, proteomics, and metabolomics to facilitate biomarker identification and validation, making it integral to drug discovery and personalized medicine. Conversely, PCR Technologies are emerging rapidly within the market, bolstered by their versatility and reliability in quantitative analysis of DNA and RNA. The growing inclination towards point-of-care testing and the increasing prevalence of infectious diseases have positioned PCR as a popular choice among researchers and clinicians alike.

### By End-use: Pharmaceutical Companies (Largest) vs. Clinical Laboratories (Fastest-Growing)

The US biomarker market demonstrates a diverse segmentation by end-use, with pharmaceutical companies capturing a significant share due to their substantial investment in biomarker research and development. Clinical laboratories follow closely, leveraging advancements in technology to enhance diagnostic capabilities and manage growing patient volumes effectively. Research institutions and diagnostic laboratories also contribute, albeit with smaller market shares, but their roles in innovation and practical application remain pivotal. Growth trends indicate a robust demand for biomarkers, driven by an increasing prevalence of chronic diseases and the need for personalized medicine. Pharmaceutical companies are at the forefront, focusing on novel therapies that require biomarker validation, while clinical laboratories are rapidly expanding capabilities to meet the rising diagnostic needs. Research institutions are pivotal in exploring new biomarkers, with funding and technological advancements further propelling market growth.

Pharmaceutical Companies: Dominant vs. Clinical Laboratories: Emerging

Pharmaceutical companies dominate the US biomarker market due to their comprehensive research and development efforts and their pivotal role in drug discovery and personalized medicine. They invest heavily in biomarker identification and validation to enhance therapeutic efficacy and patient outcomes. Conversely, clinical laboratories, while emerging, are experiencing rapid growth fueled by technological advancements and the increasing demand for diagnostic testing. Their capabilities in interpreting complex biomarker data and delivering timely results are crucial in driving patient care. Both segments are interdependent, as pharmaceutical companies rely on clinical laboratories for validation and testing, creating a dynamic interplay that accelerates innovation and market evolution.

## Competitive Benchmarking

The biomarker market exhibits a dynamic competitive landscape characterized by rapid innovation and strategic collaborations. Key growth drivers include the increasing prevalence of chronic diseases, advancements in personalized medicine, and the rising demand for early diagnostic tools. Major players such as Roche (CH), Thermo Fisher Scientific (US), and Illumina (US) are strategically positioned to leverage these trends. Roche (CH) focuses on enhancing its diagnostic capabilities through continuous innovation in biomarker discovery, while Thermo Fisher Scientific (US) emphasizes its extensive portfolio of analytical instruments and reagents to support biomarker research. Illumina (US) is dedicated to advancing genomic technologies, which are pivotal in biomarker development, thereby shaping a competitive environment that prioritizes technological advancement and strategic partnerships. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with a mix of established players and emerging companies. This fragmentation allows for diverse approaches to biomarker development, yet the collective influence of key players like Abbott Laboratories (US) and Agilent Technologies (US) is significant, as they drive innovation and set industry standards. In October 2025, Roche (CH) announced a collaboration with a leading academic institution to develop novel biomarkers for early cancer detection. This partnership is strategically important as it not only enhances Roche's research capabilities but also positions the company at the forefront of cancer diagnostics, potentially leading to significant market share growth in this critical area. Similarly, in September 2025, Thermo Fisher Scientific (US) launched a new line of biomarker assays aimed at improving the accuracy of disease detection. This move underscores the company's commitment to innovation and its role in advancing precision medicine, which is increasingly vital in the current healthcare landscape. In August 2025, Illumina (US) expanded its partnership with a prominent biotechnology firm to enhance genomic sequencing technologies for biomarker identification. This strategic action is indicative of Illumina's focus on integrating cutting-edge technology into its offerings, thereby reinforcing its competitive edge in the biomarker market. Furthermore, in July 2025, Abbott Laboratories (US) acquired a startup specializing in digital health solutions, which is likely to enhance its capabilities in biomarker analytics and patient monitoring, reflecting a broader trend towards digital transformation in healthcare. As of November 2025, current competitive trends are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into biomarker research and development. Strategic alliances are shaping the landscape, enabling companies to pool resources and expertise to accelerate innovation. The shift from price-based competition to a focus on technological advancement and supply chain reliability is evident, suggesting that future competitive differentiation will hinge on the ability to innovate and deliver reliable, high-quality biomarker solutions.

## Report Scope

| MARKET SIZE 2024 | 16.98(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 18.66(USD Billion) |
| MARKET SIZE 2035 | 48.08(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.92% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Roche (CH), Thermo Fisher Scientific (US), Abbott Laboratories (US), Agilent Technologies (US), Bio-Rad Laboratories (US), Merck KGaA (DE), Illumina (US), Qiagen (DE), PerkinElmer (US) |
| Segments Covered | Type, Application, Technology, End-use |
| Key Market Opportunities | Advancements in precision medicine drive demand for innovative biomarker solutions in diagnostics and therapeutics. |
| Key Market Dynamics | Rising demand for personalized medicine drives innovation and competition in the biomarker market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US biomarker market in 2024?**
A: The US biomarker market was valued at $16.98 Billion in 2024.

**Q: What is the projected market size for the US biomarker market by 2035?**
A: The market is projected to reach $48.08 Billion by 2035.

**Q: What is the expected CAGR for the US biomarker market from 2025 to 2035?**
A: The expected CAGR for the US biomarker market during the forecast period 2025 - 2035 is 9.92%.

**Q: Which segment of biomarkers had the highest valuation in 2024?**
A: In 2024, the Diagnostic Biomarkers segment had the highest valuation at $5.09 Billion.

**Q: What are the key applications driving the US biomarker market?**
A: Key applications include Oncology, Cardiovascular, Neurology, Infectious Diseases, and Autoimmune Diseases.

**Q: Which technology segment is expected to show significant growth in the US biomarker market?**
A: Omics Technologies is expected to show significant growth, with a valuation of $5.09 Billion in 2024.

**Q: Who are the leading companies in the US biomarker market?**
A: Leading companies include Roche, Thermo Fisher Scientific, Abbott Laboratories, and Illumina.

**Q: What was the valuation of the Prognostic Biomarkers segment in 2024?**
A: The Prognostic Biomarkers segment was valued at $3.4 Billion in 2024.

**Q: How does the market for Clinical Laboratories compare to Pharmaceutical Companies in 2024?**
A: In 2024, Clinical Laboratories were valued at $4.25 Billion, while Pharmaceutical Companies were valued at $5.09 Billion.

**Q: What is the expected growth trajectory for the Research Biomarkers segment by 2035?**
A: The Research Biomarkers segment is projected to grow from $3.69 Billion in 2024 to $11.51 Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-biomarker-market-18686*